Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Jonathan Zalevsky, insider at Nektar Therapeutics

Jonathan Zalevsky Insider Information

Jonathan Zalevsky was appointed Nektar’s Chief Research & Development Officer in October 2019 to lead all aspects of the R&D organization, including research, clinical development, regulatory affairs, and biologics process development. Dr. Zalevsky joined the Company in 2015 and has served as our Chief Scientific Officer since 2017. During his tenure at Nektar, Dr. Zalevsky’s expertise in immunology, and across biological modalities and therapeutic areas, has helped fuel the growth of the company’s immuno-oncology and immunology pipeline. Dr. Zalevsky led the early development for bempegaldeskleukin and NKTR-358.

Prior to joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. As the leading immunologist for Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development and marketed products. Prior to his work at Takeda, Dr. Zalevsky worked in research and development at Xencor, where he oversaw the discovery and development of Xencor's first four clinical-stage assets.

Dr. Zalevsky received his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco. He received dual B.S. degrees in Biochemistry and Molecular, Cellular, and Developmental Biology from the University of Colorado at Boulder.

What is Jonathan Zalevsky's net worth?

The estimated net worth of Jonathan Zalevsky is at least $1.04 million as of May 16th, 2022. Dr. Zalevsky owns 276,399 shares of Nektar Therapeutics stock worth more than $1,036,496 as of July 3rd. This net worth evaluation does not reflect any other assets that Dr. Zalevsky may own. Additionally, Dr. Zalevsky receives an annual salary of $1,160,000.00 as Insider at Nektar Therapeutics. Learn More about Jonathan Zalevsky's net worth.

How old is Jonathan Zalevsky?

Dr. Zalevsky is currently 47 years old. There are 7 older executives and no younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin M.D., Sr. VP of Clinical Devel. & Head of Immunology, who is 73 years old. Learn More on Jonathan Zalevsky's age.

What is Jonathan Zalevsky's salary?

As the Insider of Nektar Therapeutics, Dr. Zalevsky earned a total compensation package of $4,941,497.00 in 2020. Dr. Zalevsky earned a salary of $683,000.00, stock awards of $2,247,676.00, options awards of $1,501,672.00, non-equity compensation of $500,000.00, and other compensation of $9,149.00.There are 2 executives that earn more than Dr. Zalevsky. The highest earning executive at Nektar Therapeutics is Mr. Howard W. Robin, CEO, Pres & Director, who commands a salary of $2,140,000.00 per year. Learn More on Jonathan Zalevsky's salary.

How do I contact Jonathan Zalevsky?

The corporate mailing address for Dr. Zalevsky and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected] Learn More on Jonathan Zalevsky's contact information.

Has Jonathan Zalevsky been buying or selling shares of Nektar Therapeutics?

Jonathan Zalevsky has not been actively trading shares of Nektar Therapeutics in the last ninety days. As an example of a recent trade by , 0 shares of the stock in a transaction that occurred on Sunday, July 3rd. Learn More on Jonathan Zalevsky's trading history.

Who are Nektar Therapeutics' active insiders?

Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.

Are insiders buying or selling shares of Nektar Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 204,444 shares worth more than $1,906,118.52. The most recent insider tranaction occured on May, 16th when insider Jonathan Zalevsky sold 21,673 shares worth more than $85,608.35. Insiders at Nektar Therapeutics own 2.9 % of the company. Learn More about insider trades at Nektar Therapeutics.

Information on this page was last updated on 5/16/2022.

Jonathan Zalevsky Insider Trading History at Nektar Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Sell21,673$3.95$85,608.35276,399View SEC Filing Icon  
2/16/2022Sell10,912$10.95$119,486.40View SEC Filing Icon  
8/16/2021Sell7,662$13.83$105,965.46View SEC Filing Icon  
5/17/2021Sell31,111$18.30$569,331.30235,065View SEC Filing Icon  
11/23/2020Sell16,380$16.40$268,632.00250,317View SEC Filing Icon  
8/17/2020Sell26,200$19.67$515,354.00296,315View SEC Filing Icon  
2/18/2020Sell4,774$22.35$106,698.90327,073View SEC Filing Icon  
11/18/2019Sell3,960$17.97$71,161.20291,697View SEC Filing Icon  
See Full Table

Jonathan Zalevsky Buying and Selling Activity at Nektar Therapeutics

This chart shows Jonathan Zalevsky's buying and selling at Nektar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nektar Therapeutics Company Overview

Nektar Therapeutics logo
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $3.75
Low: $3.67
High: $3.84

50 Day Range

MA: $3.82
Low: $3.17
High: $4.72

2 Week Range

Now: $3.75
Low: $3.02
High: $19.37

Volume

2,373,456 shs

Average Volume

3,767,319 shs

Market Capitalization

$698.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.